Ascendis Pharma A/S (ASND) Stock

NASDAQ: ASNDUses its proprietary TransCon technology to create best-in-class therapies for unmet medical needs in endocrinology and oncology.

Ascendis Pharma A/S stock price chart

ASND interactive chart →

ASND stock quote & key statistics

Ascendis Pharma A/S earnings per share

Income →
Earnings per share

Ascendis Pharma A/S revenue & net income

Income →
RevenueNet income

Ascendis Pharma A/S annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$691.7M-$219.0M-$4.06
FY2024$363.6M-$378.1M-$6.77
FY2023$266.7M-$481.4M-$8.56
FY2022$51.2M-$583.2M-$10.40
FY2021$7.8M-$383.6M-$7.01

Fiscal year ending December 31. Source: company filings via EODHD.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a dynamic biopharmaceutical company dedicated to addressing unmet medical needs through innovative therapies. Established in 2006 and headquartered in Hellerup, Denmark, Ascendis Pharma focuses on pioneering treatments that offer transformative solutions to patients worldwide.

At the forefront of Ascendis Pharma's portfolio is SKYTROFA, a groundbreaking therapy designed for individuals suffering from growth hormone deficiency (GHD). The company also leads in the development of TransCon Growth Hormone, catering to pediatric and adult GHD, as well as Turner syndrome. Additionally, Ascendis Pharma advances TransCon Parathyroid Hormone for adults with hypoparathyroidism and TransCon C-type natriuretic peptide targeting achondroplasia.

Further enhancing its pipeline, Ascendis Pharma is actively developing TransCon toll-like receptors 7/8 agonist for intratumoral delivery and TransCon IL-2 �/? for systemic delivery, demonstrating its commitment to expanding therapeutic options across various medical domains. With a steadfast commitment to innovation and patient-centric solutions, Ascendis Pharma continues to shape the future of biopharmaceuticals through cutting-edge research and development initiatives.

Ascendis Pharma A/S stock FAQ

What is the Ascendis Pharma A/S stock ticker symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol ASND.

What sector and industry is Ascendis Pharma A/S in?

Ascendis Pharma A/S is classified in the Healthcare sector, Biotechnology industry.

How many employees does Ascendis Pharma A/S have?

Ascendis Pharma A/S has about 1,189 full-time employees.

What were Ascendis Pharma A/S's revenue and earnings last fiscal year?

Ascendis Pharma A/S reported revenue of $691.7M and net income of -$219.0M in fiscal 2025, with earnings per share of -$4.06. Revenue grew 90.2% from the prior year.

Is Ascendis Pharma A/S in the Russell 1000?

Yes. Ascendis Pharma A/S (ASND) is a component of the Russell 1000, which tracks roughly the 1,000 largest U.S. companies.

When did Ascendis Pharma A/S go public?

Ascendis Pharma A/S stock began trading on January 28, 2015.

Russell 1000 Biotechnology stocks

All Russell 1000 →